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ABSTRACT
In the present study, we investigated the effects of basal and intra-arterial infusion of bradykinin
on unstressed forearm vascular volume (a measure of venous tone) and blood ﬂow in healthy
volunteers (n=20) and in chronic heart failure patients treated with ACEIs [ACE (angiotensin-
converting enzyme) inhibitors] (n=16) and ARBs (angiotensin receptor blockers) (n=14). We
used radionuclide plethysmography to examine the effects of bradykinin and of the bradykinin
antagonists B9340 [B1 (type 1)/B2 (type 2) receptor antagonist] and HOE140 (B2 antagonist).
Bradykinin infusion increased unstressed forearm vascular volume in a similar dose-dependent
manner in healthy volunteers and ARB-treated CHF patients (healthy volunteers maximum
12.3+ −2.1%, P<0.001 compared with baseline; ARB-treated CHF patients maximum 9.3+ −3.3%,
P<0.05 compared with baseline; P=not signiﬁcant for difference between groups), but the
increase in unstressed volume in ACEI-treated CHF patients was higher (maximum 28.8+ −7.8%,
P<0.001 compared with baseline; P<0.05 for the difference between groups). In contrast,
while the increase in blood ﬂow in healthy volunteers (maximum 362+ −9%, P<0.001) and in
ACEI-treated CHF patients (maximum 376+ −12%, P<0.001) was similar (P=not signiﬁcant for
the difference between groups), the increase in ARB-treated CHF patients was less (maximum
335+ −7%, P<0.001; P<0.05 for the difference between groups). Infusion of each receptor
antagonist alone similarly reduced basal unstressed volume and blood ﬂow in ACEI-treated CHF
patients, but not in healthy volunteers or ARB-treated CHF patients. In conclusion, bradykinin
does not contribute to basal venous tone in health, but in ACEI-treated chronic heart failure
it does. In ARB-treated heart failure, venous responses to bradykinin are preserved but arterial
responses are reduced compared with healthy controls. Bradykinin-mediated vascular responses
in both health and heart failure are mediated by the B2, rather than the B1, receptor.
INTRODUCTION
Bradykinin is a potent endothelium-dependent dilator of
the resistance vessels in health [1,2] and in CHF [chronic
HF (heart failure)] [3]. In patients treated with ACEIs
[ACE (angiotensin-converting enzyme) inhibitors],
bradykinin contributes to the regulation of basal vascular
tone in the resistance vessels [4] and in the pulmonary
circulation [5]. In health, bradykinin is also a potent
dilator of conduit veins [6]; however, the physiology
of small veins and venules that make up most of the
venous volume differs markedly from that of conduit
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veins [7]. Since a large proportion of total blood volume
is contained within these vessels, even small changes
in the tone of these ‘capacitance’ veins will inﬂuence
cardiac pre-load. This is particularly relevant in CHF.
Understanding the receptors involved in mediating
these effects is also important since they are potential
therapeutic targets. To the best of our knowledge the
direct local effects of bradykinin on capacitance veins
have not been assessed in health or in CHF in humans.
In health, bradykinin mediates its effects primarily via
its constitutively expressed B2 receptor (type 2 receptor)
[8]. In arteries there is evidence to suggest that there is a
proportionately higher expression of the B1 bradykinin
receptor (type 1 receptor) in CHF [3,4], either due to up-
regulationoftheB1receptorortodown-regulationofthe
B2 receptor [9]. The contribution of B1 and B2 receptors
to bradykinin-induced changes in venous capacitance has
not been evaluated in health or in CHF. Furthermore,
endothelial dysfunction affects arterial vessels in CHF
and an impaired dilator response to bradykinin might
be expected. In contrast, we have previously shown
preservation of endothelium-dependent responses to
carbachol [10], and also preservation of the NO-depend-
ent response to ANP (atrial natriuretic peptide) [11],
in the forearm capacitance bed of patients with CHF,
despite attenuation of responses in arteries. Preservation
of responses to bradykinin in capacitance vessels might
thus be anticipated in CHF.
To assess the role of bradykinin and to identify the
receptors involved in mediation of its effects on cap-
acitance veins in both health and in treated CHF, we
tested three hypotheses. First, that bradykinin modulates
basal forearm venous capacitance in CHF patients
treated with ACEIs, but not in healthy volunteers or in
CHF patients treated with ARBs (angiotensin receptor
blockers). Secondly, we hypothesized that in CHF
patients the response to bradykinin is impaired in
resistance vessels, but preserved in capacitance vessels.
Thirdly, we hypothesized that B1-mediated effects are
greater in both resistance and capacitance vessels in CHF
patients when compared with healthy controls.
MATERIALS AND METHODS
Subjects
We studied 20 healthy volunteers and 30 patients with
stable treated CHF associated with LV (left ventricular)
systolic dysfunction (ejection fraction <40%) who
had NYHA (New York Heart Association) class II–III
symptoms. Of the 30 patients with stable treated CHF,
16 patients were on maximal tolerated doses of ACEIs
and 14 patients were on maximally tolerated doses of
ARBs. Medications and doses are listed in Table 1. All
subjects were on an ad libitum diet, but refrained from
caffeine for at least 12 h prior to the study. Smoking was
an exclusion criterion for the volunteers, and there were
no current smokers in the patient group. All medications
were withheld for at least 24 h prior to the study. Patient
and subject characteristics are summarized in Table 1.
Written informed consent was provided by all subjects,
and the study was approved by the local research ethics
committee.
Subjects rested in a supine position in a temperature-
controlled laboratory (21–22◦C). An 18-gauge cannula
was inserted into a vein in the ante cubital region of the
dominant arm and radiolabelling of RBCs (red blood
cells) was carried out as described previously [7]. A
27-gauge arterial needle (Coopers Engineering) mounted
on to a 16-gauge epidural catheter was then inserted into
the non-dominant brachial artery, and kept patent by
continuous infusion of 0.9% saline. Following 20 min
rest and a 15 minute intra-brachial 0.9% saline infusion,
baseline FBF (forearm blood ﬂow) and FVV (forearm
venous volume) were measured.
FBF was measured using standard mercury in silastic
strain gauge plethysmography (Hokanson), as described
previously [12,13]. The changes in the infused arm were
corrected for changes in the control arm.
FVV was measured by combining venous occlusion
plethysmography and equilibrium blood-pool scinti-
graphy, as described previously [7,11]. In brief, following
modiﬁedexvivoradiolabellingofRBCswithtechnetium
(Tcm99), blood pool volume/pressure relationships were
constructed for both forearms, by inﬂating upper-arm
cuffs to 10, 20 and 30 mmHg for 1 min at each venous
occlusion pressure. Dynamic images were acquired
continuously, ﬁrst during infusion of normal saline and
then during each of the infusions as described below.
After correction for physical decay, the scintigraphic
vascular volume was plotted against the occluding
cuff pressure. Linear regression was performed and a
linear model was adopted if the R2 value was >0.9.
Parallel shifts of the relationhip indicates a change in
venous tone. The intercept of the regression curve with
the y-axis reﬂects ‘unstressed’ venous volume (i.e. the
volume that would exist at a theoretical zero transmural
pressuregradient).Theunstressedvolumeduringnormal
saline infusion was arbitrarily denoted as 100%, and
subsequent readings were expressed as a percentage of
this value. Changes in the infused arm were then cor-
rected for those occurring in the control arm.
Measurements of FBF and FVV were repeated after
each infusion of bradykinin and receptor antagonists in
the experiments described below.
Vascular response to exogenous
bradykinin
In all subjects, bradykinin (Clinalfa) was infused incre-
mentally at 31.8 ng/min (30 pmol/min) and 318 ng/min
(300 pmol/min) for 6 min at each dose.
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Table 1 Subject characteristic
Values are means+ −S.E.M. or mean (range). The total daily doses of the drugs are listed. DCM, dilated cardiomyopathy; IHD, ischaemic heart disease; MUGA EF,
multiple-gated acquisition ejection fraction.
Parameter Healthy volunteers (n=20) ACEI-treated CHF patients (n=16) ARB-treated CHF patients (n=14)
Age (years) 58 (52–68) 64 (50–80) 66 (50–80)
Gender (male/female) 11:9 14:2 8:6
Aetiology (IHD/DCM) 11:5 12:2
NYHA class (II/III) 14:2 11:3
Treated hypertension (n)8 6
Treated diabetes (n)4 3
Medication (n)
β-Blockers 10 11
Diuretics 12 12
Aspirin 11 3
Nitrate 5 6
Lipid-lowering drugs 11 10
Digoxin 3 3
Warfarin 6 5
Ramipril (dose 10 mg) 5
Ramipril (dose 5 mg) 4
Perindopril (dose 4 mg) 3
Lisinopril (dose 20 mg) 2
Lisinopril (dose 2.5 mg) 1
Fosinopril (dose 40 mg) 1
Losartan (dose 50 mg) 4
Candesartan (dose 8 mg) 4
Losartan (dose 100 mg) 2
Losartan (dose 25 mg) 2
Valsartan (dose 160 mg) 2
MUGA EF (%) 54+ −13 8 + −23 5 + −3
Baseline FBF (ml·min−1 ·100 ml of forearm volume−1)1 . 8 + −0.2 1.7+ −0.2 1.7+ −0.3
Baseline FVV (radioactive counts in the infused forearm) 956+ −50 899+ −148 947+ −41
Assessment of antagonism of exogenous
bradykinin
We studied the effects of the speciﬁc B2 receptor
antagonist HOE140 (Clinalfa) in 12 healthy volunteers
and15patients(n=10onACEIsandn=5onARBs)and
the non-speciﬁc B1/B2 receptor antagonist B9340
(Clinalfa) in eight healthy volunteers and 15 patients
(n=6 on ACEIs and n=9 on ARBs). Following assess-
ment of the vascular response to exogenous bradykinin,
HOE140 or B9340 was co-infused at 13.5 nmol/min
(17.6 μg/min and 17.8 μg/min respectively) with brady-
kinin at 318 ng/min (300 pmol/min) for 6 min. A 40:1
antagonist/bradykinin ratio was maintained to ensure an
adequate local antagonist concentration.
Assessment of endogenous bradykinin
activity
Following assessment of the effects of the receptor
antagonists, 0.9% saline was infused and measurements
were allowed to return to baseline and equalize between
the infused and control arms. HOE140 or B9340 was
then infused at 13.5 nmol/min (17.6 μg/min and 17.8 μg/
min respectively) for a further 6 min.
BP (blood pressure) was monitored continuously with
ﬁnger photo-plethysmography (TNO-TPD Biomedical
Instrumentation). The HR (heart rate) was recorded
throughout the study via a three-lead ECG.
Statistics
The sample size was based on sample-size calculations,
with 80% power to detect a 10% change in unstressed
FVV, with a signiﬁcance at the 0.05 level with a σ
of 10%. Statistical analysis was performed using SPSS
version11.5.1.Allvaluesareexpressedasmeans+ −S.E.M.
and a P value of <0.05 was considered signiﬁcant.
Within each subject group (controls, ARB-treated CHF
patients and ACEI-treated CHF patients), one-way
ANOVA was carried out for the absolute FBF ratios
between the infused and the control arms for the analysis
of FBF response to bradykinin. Two-way ANOVA
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Table 2 Changes in FBF and FVV with bradykinin (corrected for control arm)
Values are means+ −S.E.M. indicating the percentage change from baseline. *P <0.05, ‡P <0.01 and †P <0.001 compared with baseline (measured by using
one-way ANOVA)
FBF FVV
ACEI-treated ARB-treated ACEI-treated ARB-treated
Infusion Healthy volunteers CHF patients CHF patients Healthy volunteers CHF patients CHF patients
Bradykinin (at 31.8 ng/min) 231+ −9‡ 262+ −11‡ 220+ −10‡ 2.7+ −1.6 11.2+ −3.1* 1.1+ −2.1
Bradykinin (at 318 ng/min) 362+ −9† 376+ −12† 335+ −17† 12.3+ −2.1† 28.8+ −7.8† 9.3+ −3.3*
was performed to assess between-group differences,
and Bonferroni correction was applied for multiple
comparisons. One-way ANOVA was carried out for
the percentage changes of unstressed FVV between the
infused arm and the control arm for the analysis
of unstressed FVV response to bradykinin, and two-
way ANOVA was performed to assess between group
differences.Two-wayANCOVA(analysisofcovariance)
was carried out for the analysis of the two antagonists
B9340 and HOE140, between each pair of the three sub-
ject groups, using the FBF and unstressed FVV dif-
ferencesatmaximumbradykinininduceddilatationasthe
covariate. A paired sample Student’s t test was used for
theanalysisofbasalbradykinineffectswithineachgroup.
RESULTS
Subject characteristics are shown in Table 1.
BP and HR did not change signiﬁcantly from baseline
during or at the end of the infusions (baseline BP
120/65+ −4/4, 110/60+ −8/6 and 115/64+ −12/8 mmHg
for healthy volunteers, ACEI-treated CHF patients and
ARB-treated CHF patients respectively compared with
BP during ﬁnal infusion 118/65+ −6/4, 118/58+ −14/10
and 112/60+ −16/12 mmHg respectively for the groups
as above).
Effects of bradykinin infusion on
resistance vessels
FBF increased signiﬁcantly in the infused compared
with non-infused arms in healthy volunteers and in both
CHF patient groups (ACEI-treated and ARB-treated)
(see Table 2). The increase in FBF in healthy volunteers
and ACEI-treated CHF patients was similar, but both
were signiﬁcantly higher (P<0.05, measured by using
two-way ANOVA) than in ARB-treated CHF patients
(Figure 1).
Effects of bradykinin infusion on
capacitance vessels
Unstressed FVV increased signiﬁcantly in all three
groups. The percentage increases from baseline are
summarized in Table 2. The unstressed FVV increase
Figure 1 Absolute changes in the FBF ratio between the
infused and control arms in response to bradykinin
BK 30, FBF during the infusion of bradykinin at 30 pmol/min; BK 300, FBF
during the infusion of bradykinin at 300 pmol/min. *P <0.05 (measured by
using two-way ANOVA).
Figure 2 Changes in FVV as a percentage of the baseline in
response to bradykinin
BK 30, FVV during the infusion of bradykinin at 30 pmol/min; BK 300, FVV
during the infusion of bradykinin at 300 pmol/min. *P <0.05 (measured by
using two-way ANOVA).
in ACEI-treated CHF patients was signiﬁcantly higher
(P<0.05, measured by using two-way ANOVA) than in
both healthy volunteers and ARB-treated CHF patients
(Figure 2).
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Figure 3 Percentage changes in the FBF ratio between the
infused and control arms during infusion of bradykinin alone
and co-infusion with B9340 or HOE140
BK 300, FBF during the infusion of bradykinin at 300 pmol/min. *P <0.05
(measured by using two-way ANCOVA).
Figure 4 Changes in FVV as a percentage of the baseline
during infusion of bradykinin alone or co-infusion with
B9340 or HOE140
BK 300, FVV during the infusion of bradykinin at 300 pmol/min. *P <0.05
(measured by using two-way ANCOVA).
Co-infusion of bradykinin with receptor
antagonists
B9340 and HOE140 both attenuated the FBF and
unstressedFVVresponsesto318 ng/min(300 pmol/min)
infusion of bradykinin, to a similar extent in all three
groups (P<0.05, measured by using ANCOVA; Fig-
ures3and4).Therewasnosigniﬁcantdifferencebetween
B9340 and HOE140 (P>0.05, measured by ANCOVA).
Baseline bradykinin activity
Infusion of B9340 or HOE140 did not reduce the FBF or
unstressed FVV in healthy volunteers or in ARB-treated
CHFpatients(P>0.05,measuredbyusingapairedttest;
Figures 5A–5D). For HOE140 the percentage changes in
FBF were −4.4+ −11.2 and 4.6+ −12.8%, and the percent-
age changes in unstressed FVV were −0.4+ −1.8% and
−0.7+ −1.9% respectively (P>0.05, measured by using a
paired t test) for normal healthy volunteers and for ARB-
treatedCHFpatients;however,bothB9340andHOE140
reduced FBF and unstressed FVV in ACEI-treated CHF
patients (P<0.05, measured by using a paired t test;
Figures 5A–5D). For HOE140 the percentage change in
FBF was −27.8+ −10.8% (P>0.05, measured by using
ap a i r e dt test) and the percentage change in unstressed
FVV was −4.0+ −1.8% (P>0.05, measured by using a
paired t test) in ACEI-treated CHF patients.
DISCUSSION
The primary focus of bradykinin-related research in the
past has been on the peripheral resistance vasculature [1–
4], the coronary arteries [14] and the pulmonary circul-
ation [5]. A number of studies have examined the effects
of bradykinin on the dorsal hand vein [6,15]; however,
it is increasingly clear that such conduit veins may have
different physiological characteristics to the small veins
and venules that contribute most to the capacitance vas-
culature[7].AlthoughMasonandMelmon[16]examined
the effects of systemic infusions of bradykinin on venous
capacitance, two important caveats should be considered.
First,systemicinfusionsofbradykininleadtostimulation
of baroreﬂexes and other peripheral and systemic
compensatory responses. Indeed, there is evidence that
bradykininmayalterbaroreﬂexsensitivity[17].Secondly,
venouscapacitancewasmeasuredusingstrain-gaugeven-
ous occlusion plethysmography. Bradykinin is known
to affect capillary permeability, thus interpretation of
limb volume changes as being due to changes in vascular
volume may be very misleading [7]. To our knowledge,
thepresentstudyistheﬁrsttodirectlymeasurechangesin
venous tone and regional vascular volume in response to
local infusions of bradykinin in healthy subjects. In addi-
tion to demonstrating modulation of FVV by exogenous
bradykinin, the results of the present study demonstrate
that endogenous bradykinin does not contribute to the
regulation of basal resistance or capacitance vascular
tone in the human forearm in health. We also conﬁrm
that, in health, bradykinin exerts its effects on both resis-
tance and capacitance vessels through the B2 receptor.
In CHF patients treated with ACEIs, the forearm
resistance vessel responses to bradykinin were similar
to those of healthy controls, but in patients treated with
ARBs they were signiﬁcantly reduced. The most likely
explanation for these observations is that endothelial
dysfunction in CHF patients reduces responsiveness
of resistance vessels to bradykinin, and that ACEI
treatment increases local concentrations to a greater
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Figure 5 Changes in FBF and FVV in healthy volunteers compared with ACEI-treated CHF patients and ARB-treated CHF
patients.
(A) Percentage changes in the FBF ratio between the infused and control arms during infusion of B9340, after the period of normal saline washout. *P <0.05 (measure
by paired Student’s t test). (B) Changes in FVV as a percentage of the baseline during infusion of B9340 after the period of normal saline washout. *P <0.05 (mea-
sured by using a paired Student’s t test). (C) Percentage change in FBF during infusion of B9340 or HOE140 in ACEI-treated CHF patients after the period of normal
saline washout. *P <0.05 (measured by using a paired Student’s t test). (D) Changes in FVV as a percentage of the baseline during infusion of B9340 or HOE140
in ACEI-treated CHF patients after the period of normal saline washout. P <0.05 (measured by using a paired Student’s t test).
extent than ARBs (by inhibition of bradykinin
breakdown), resulting in ‘preservation’ of the response
to infused bradykinin. ACEIs and ARBs may ameliorate
endothelialdysfunctioninsomediseasestates[18,19],but
they do not normalize it. Another possible explanation
is that B2 receptors are ‘re-sensitized’ in the presence
of ACEIs via the inﬂuences of angiotensin-(1–9) and
angiotensin-(1–5) [20]. Our ﬁnding of the preservation
oftheresistancevesselresponsetoexogenousbradykinin
in ACEI-treated CHF patients is consistent with those
of Maguire et al. [21], but our ﬁnding that responses
in ARB-treated CHF patients are impaired is, to the
best of our knowledge, novel. Davie et al. [3] observed
reduced responsiveness in CHF patients treated with
ARBs compared with those treated with ACEIs, but
there was no healthy control group for comparison.
Importantly,incontrastwithourﬁndingsinresistance
vessels, we found that venous responses to bradykinin
in CHF patients treated with ARBs were similar to
those of healthy controls, and that responses in the
ACEI-treated CHF patients were higher than those of
healthy controls. Although the mechanism is unproven
we propose that this observation is most likely due
to preservation of endothelial function in capacitance
vessels in CHF patients. We previously demonstrated
that in ACEI-treated CHF patients, there was marked
arterial endothelial dysfunction, but preservation of
endothelium-dependent responses to carbachol in the
capacitancevessels[10].Furthermoreinanotherstudywe
showed that much of the responses of forearm resistance
and capacitance vessel response to ANP is mediated via
endothelium-dependent NO release, and that in CHF
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there was blunting of this NO-dependent component in
the resistance, but not the capacitance vessels [13].
There is histological evidence that the expression
of B1 and B2 receptors may shift preferentially towards
B1 expression in CHF, with a reduction in B2 receptor
expression in end-stage CHF [9]. The studies of Davie
et al. [3] and Witherow et al. [4] together indicate that
bradykinin exerts basal effects on forearm resistance
vesselsinCHFpatientstreatedwithACEIsandthatthese
effects are mediated via B1, rather than B2, receptors. In
contrast, in a study using B1 receptor agonists, Cruden
et al. [22] refuted any signiﬁcant resistance vessel role
for the B1 receptor in CHF. The ﬁndings of the present
study are consistent with the latter, and demonstrate that
both receptor antagonists (B9340 and HOE140) negated
the effects of exogenous bradykinin equally in resistance
and capacitance vessels of the forearm to a similar extent.
Most of our patients were only moderately symptomatic
(NYHA II). Most of the patients in the Cruden et al. [22]
study also had relatively mild (NYHA II) symptoms. In
contrast, patients in the Witherow et al. [4] study were
mainly severely symptomatic (NYHA III or IV). Thus
our patient group may not manifest the shift of receptor
expression. We draw the conclusion that in treated CHF
patients with moderate symptomatic limitation, the
effects of exogenous bradykinin are primarily mediated
via the B2 receptor. It is possible that in more severe HF
B1-mediated effects may be more important.
We also show that endogenous bradykinin contributes
to basal venous tone in ACEI-treated CHF patients
as well as conﬁrming the previous ﬁndings [4] that
endogenous bradykinin contributes to modulation of the
basal forearm resistance in ACEI-treated CHF patients.
However, in contrast with Witherow et al. [4], the results
of the present study show that these basal effects were
also antagonized by HOE140 and B9340 to a similar
extent, reinforcing our ﬁnding that the B2 receptor
remains the expressed receptor type in moderate treated
CHF.
It has been suggested that due to inhibition of PG
(prostaglandin) synthesis, aspirin might attenuate the
beneﬁcial effects of ACEIs [23]. Several clinical trials
have shown that aspirin treatment may increase hospital
admissions due to worsening HF [24–26]. However,
the balance of available evidence suggests that low-dose
aspirin does not impair the arterial dilation induced by
ACEIs in CHF [27], nor does it blunt the beneﬁcial
effects on mortality [28,29]. Low-dose aspirin inhibits
thromboxane formation and has little or no effect on
prostacyclin PGI2, the cyclo-oxygenase-dependent
second messenger for bradykinin [30]. In addition, any
effect on PGI2 is short lasting (less than 6 h) [31,32] in
comparison with effects on thromboxane. We did not
exclude patients who had been taking low-dose aspirin
(<150 mg) because the ethics committee considered
it unethical to do so, but we ensured that aspirin was
withheld for at least 48 h prior to the experiments, by
which time vascular effects would have ceased.
The objective of the present study was to show
that bradykinin is an important mediator of venous
tone in health and in CHF. However, in dissecting the
mechanisms involved in mediating the effects that we
have shown, our studies are limited by the lack of direct
assessment of the NO-dependent component. However,
addition of another infusion step with LNMMA (NG-
monomethyl-l-arginine) would have extended the
studies beyond 3 h in duration. We have found it
impossibleforsubjectstoremainstillandrelaxedbeyond
3 h with an arterial needle in situ. No dose-comparison
studies exist between ACEIs and ARBs. Thus we cannot
quantitatively determine whether the doses that our
patients were on inhibited the angiotensin–aldosterone
axis to a comparable degree. This weakness needs to be
considered when comparing the differences we identiﬁed
between ACEIs and ARBs. Furthermore, as the patients
were already on either ACEIs or ARBs, it is possible,
at least in theory, that baseline differences in physiology
may have existed prior to initiation of treatment.
In conclusion, we demonstrate that the FBF response
to bradykinin is impaired in ARB-treated CHF patients,
but is not in ACEI-treated patients. We also demonstrate
that forearm venous capacitance is increased by exogen-
ous bradykinin in both health and in CHF, and that the
response is preserved in ARB-treated CHF patients and
increased in ACEI-treated CHF patients compared with
healthycontrols.Resistanceandcapacitancevesseleffects
are mediated via the B2 receptor in both health and in
CHF. Bradykinin does not play a role in modulating
basal forearm venous tone in health, but contributes to
the basal forearm venous tone in ACEI-treated CHF
patients, but not in ARB-treated CHF patients.
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